Old Dominion vs XPO
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Old Dominion and XPO side by side, using each one’s latest annual report. Here is what stands out:
- XPO is the larger business, with $8.2B of revenue in fiscal 2025 against $5.5B for Old Dominion.
- XPO grew revenue faster (1.1%, against −5.5%).
- Old Dominion kept more of each dollar of sales as operating profit (24.8% operating margin, against 8.0%).
- Old Dominion turned more of its sales into free cash flow (17.4% FCF margin, against 4.0%).
- Old Dominion earned a higher return on the capital invested in it (24.3%, against 9.5%).
- Investors pay more for each dollar of XPO’s earnings: a P/E of 53.9x against 35.1x for Old Dominion.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Old Dominion
ODFL
9/10
5-year growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
XPO
XPO
1/10
Revenue growth
Side by side
Best in the row
| Latest fiscal year | ODFL FY25 | XPO FY25 |
|---|---|---|
| Size | ||
| Market cap | $38.1B | $21.5B |
| Revenue | $5.5B | $8.2B |
| Free cash flow | $955M | $329M |
| Net income | $1.0B | $316M |
| Growth | ||
| Revenue growth | −5.5% | 1.1% |
| 5-year growth | 6.5% | 5.8% |
| Share count change | −2.3% | −0.8% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 24.8% | 8.0% |
| Net margin | 18.6% | 3.9% |
| FCF margin | 17.4% | 4.0% |
| Return on capital | 24.3% | 9.5% |
| Return on equity | 23.9% | 18.3% |
| Balance sheet | ||
| Net debt | −$80.1M | $3.2B |
| Net debt / EBITDA | −0.1x | 2.8x |
| Dividends and buybacks | $966M | $125M |
| Valuation & quality | ||
| P/E | 35.1x | 53.9x |
| Piotroski F-score | 6 | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.